EVALUATION OF THE ROLE OF ANTIOXIDANT ENZYME PARAOXONASE 1 IN COPD

*Balakrishnan Menon¹, Charanjeet Kaur² and Gaki Nima¹

¹Department of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, New Delhi and ²Department of Biochemistry, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi

*Author for Correspondence

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is characterized by progressive, irreversible airflow limitation associated with airway inflammation (Pauwels et al., 2001). It is a leading cause of chronic morbidity and mortality worldwide. The importance of oxidative stress in both lungs and systemic circulation is well established in the pathogenesis of COPD (Chavez et al., 2007). In healthy subjects there is a balance between oxidants and antioxidants, keeping the extracellular environment in a reduced state. But there is limited information on the respiratory epithelial antioxidant defenses in smokers, and less in COPD.

Cigarette smoking, air pollution, an increase of free radicals in respiratory epithelial cells by inflammation and infections are the leading causes of oxidative stress in COPD (Chen et al., 2004; Pryor and Stone, 1993). Free radicals cause an imbalance between oxidants and antioxidants. An imbalance in favor of oxidants may cause oxidative damage to the air space epithelial cells. Lipid peroxidation occurs at the cell membrane by the effect of free radicals (Pryor and Stone, 1993).

Paraoxonase1 (PON1) in the lung may have a protective role from oxidative stress. PON1 is an antioxidant enzyme which is localized in Clara cells, endothelial cells and type 1 cells of the alveolar epithelium in the lung and may have a role in protection from oxidative stress. It is able to hydrolyze paraoxon, which is a potent inhibitor of cholinesterases. It is entirely complexed to HDL and has an antioxidant role in the protection of LDL from oxidative stress in blood. Clara cell is one of the oxidant resistant airway cells in all species and secretions of Clara cells have a role in protection from oxidative stress. Clara cells are replaced by mucous cells in smokers and there is a reduction in Clara cells in COPD patients and in smokers. Smoking which causes vital damage at the airspace epithelium may also cause reduction in the levels of PON1 (Chavez et al., 2007). In the recent years, several studies have showed that extracts of cigarette smoke inhibited the activity of PON1 (Aharoni et al., 2004; Moren et al., 2008).

The paraoxonases (PON1, PON2, PON3) are basically lactonases with one of the broadest known substrate specificities (Chow, 1993; Eckerson et al., 1993). All three PONs metabolise 5-hydroxy cicosate traeomic acid 1,5 lactone and 4-hydroxy docosahexaenoic acid which are derived from arachidonic acid. PON3 exclusively hydrolyses lovastatin and spironolactone whereas organophosphates are exclusively hydrolysed by PON1 which has additional esterase activity.

PON1 protein is synthesized mostly in liver and is released by a docking process, i.e. HDL particles transiently associate with the cell membrane and remove PON1 from the membrane (Isik et al., 2005). Unlike PON2 and PON3, it has efficient esterase activity towards many organophosphates (OPs) including paraoxynase (Isik et al., 2005). The PON1 gene is located on the long arm of chromosome 7 at q21-q22 regions (Draganov et al., 2005).

Components of inflammatory cascade such as inflammatory cells, cytokines, oxidative stress biomarkers, and inflammatory indicators like C-reactive protein (CRP) are the potential biomarkers that can be used in the diagnosis and prognosis of COPD. Chronic inflammation in the pulmonary tissue is also associated with systemic effects. CRP is often used as a clinical marker of acute systemic inflammation. Since low-grade inflammation is evident in COPD, high sensitive CRP (hs-CRP) levels are raised in these patients (Yende et al., 2006). C-Reactive Protein (CRP) is an acute phase protein synthesized predominantly by the hepatocytes in response to tissue damage or inflammation.

In this study, we investigated the possible relationship between serum PON levels in the COPD patients, smokers without COPD and the non-smoker healthy subjects and its correlation with hs CRP.

© Copyright 2014 | Centre for Info Bio Technology (CIBTech)
MATERIALS AND METHODS

Methods
The study was conducted at Viswanathan Chest hospital attached to Vallabhbhai Patel Chest Institute (VPCI), University of Delhi over a period of 1 year. Written informed consent was obtained from each patient prior to admission to the study.

Study Subjects
A total of 60 patients with the diagnosis of chronic obstructive pulmonary disease (COPD) were recruited. They consisted of 15 patients each of mild, moderate, severe and very severe COPD as per GOLD Guidelines. 30 subjects were taken as control; they consisted of 15 normal subjects and 15 healthy smokers. These patients and controls were subjected to a detailed clinical examination that includes, general physical examination, systemic examination of the respiratory and cardiovascular systems.

High Sensitivity C-reactive Protein (hs-CRP)
Hs-CRP was measured in patients’ serum and control serum by the ELISA method. Normal expected values: 0.068 – 8.2 mg / lit.

Paraoxonase 1 (PON1)
PON 1 was measured using spectrophotometry method and values were expressed in kU/L.

RESULTS AND DISCUSSION

Results
Profile of Patients and Controls in the Study
The mean age of Controls was 24.93 + 2.79 yrs, Healthy smokers was 38.67 + 9.82 yrs, Mild COPD was 52.47 + 13.35 yrs, Moderate COPD was 53.27 +18.04 yrs, severe COPD was 58.93 + 7.38 yrs & very severe COPD was 55.73 + 7.83 yrs (Table 1).

Paraoxonase 1 (PON 1)
The level of PON1 was seen to decrease with the increasing severity of COPD (Table 2). In mild COPD it was 146.18 + 61.20 KU/L, in moderate COPD it was 90.30 + 29.99 KU/L, in severe COPD it was 84.45 + 34.89 KU/L and very severe COPD it was 143.19 + 35.76 KU/L. Levels were lower in healthy smokers (143.26 + 55.64 KU/L) as compared to controls (192.55 + 54.71 KU/L). The difference of means was significant on ANOVA. The difference of means between control and moderate COPD was 102.24 + 17.15 KU/L (p<0.01), between control and severe COPD was 108.09 + 17.15 KU/L (p<0.01), between healthy smoker & moderate COPD was 52.96 + 17.15 KU/L (p=0.041), between healthy smoker and severe COPD was 58.80 + 17.15 KU/L (p=0.014), between mild and moderate COPD was KU/L 55.88 + 17.15 (p=0.024), between mild and severe COPD was 61.72 + 17.15 KU/L (p=0.008), between moderate & very severe COPD was 52.89 + 17.15 KU/L (p=0.041) and between severe and very severe COPD was 58.74 + 17.15 KU/L (p=0.014).

High Sensitive C-reactive protein (hsCRP)
The levels of hsCRP were seen to increase with the increasing severity of COPD (Table 2). In mild COPD it was 0.94 + 0.68 mg/L, in moderate COPD it was 2.54 + 0.61 mg/L, in severe COPD it was 4.87 + 2.22 mg/L and very severe COPD it was 6.74 + 5.36 mg/L. The mean levels of hsCRP in healthy smokers (0.93 + 0.71 mg/L) were higher than control (0.65 + 0.43 mg/L). The difference of mean was found to be significant on AVOVA. The difference of means between control & severe COPD was 4.23 + 0.88 mg/L (p<0.01), between control & very severe COPD was 6.09 + 0.88 mg/L (p=0.01), between healthy smoker & severe COPD was 3.94 + 0.88 mg/L (p<0.01), between healthy smoker & very severe COPD was 5.81 + 0.88 mg/L (p<0.01), between mild & severe COPD was 3.93 + 0.88 mg/L (p<0.01), between mild & very severe COPD was 5.79 + 0.88 mg/L (p<0.01) and between moderate & very severe COPD was 4.20 + 0.88 mg/L (p<0.01).

Pulmonary Function Tests
The mean values of spirometry parameters of controls and patients are depicted in Table 3.
Paraoxonase1 (PON1)

PON1 correlated positively with pulmonary function parameters. FEV₁ Pre (r = 0.386, p < 0.01), FEV₁ Post (r = 0.373, p < 0.01) (Figure 1), FVC Pre (r = 0.339, p < 0.01), FVC Post (r = 0.339, p < 0.01) (Figure 2), FEF₂₅₋₇₅ pre (r = 0.410, p < 0.01) and FEF₂₅₋₇₅ Post (r = 0.372, p < 0.01) (Figure 3).

HS-CRP

hsCRP correlated negatively with PON1 (r = -0.273, p < 0.01) (Figure 4) and Pulmonary function parameters FEV₁ Pre (r = -0.600, p < 0.01), FEV₁ Post (r = -0.602, p < 0.01), FVC Pre (r = -0.521, p < 0.01), FVC Post (r = -0.509, p < 0.01), FEF₂₅₋₇₅ pre (r = -0.494, p < 0.01) and FEF₂₅₋₇₅ Post (r = -0.489, p < 0.01).

Discussion

Systemic Inflammatory Markers in COPD

High Sensitivity C-Reactive Protein (hsCRP) in COPD

C-Reactive protein (CRP) was first discovered by Tilet and Francis (1930) in the plasma of pneumonia patients, and was named because of its ability to bind and precipitate the C-polysaccharide of pneumococcus (Gillman et al., 2000). CRP is synthesized in the liver and is normally present in serum or plasma at levels less than 0.3 mg/dl. Its physiological roles are multiple but with several functions similar to those immunoglobulins, CRP appears to function in host defense (Baumann et al., 1994).

CRP is one of the acute-phase proteins, which rise during general, nonspecific response to a wide variety of diseases. This includes infections by gram-positive and gram-negative organisms, rheumatoid arthritis, malignancies, Guillain–Barre syndrome and multiple sclerosis, tuberculosis and many other necrotic and inflammatory (Yudkin et al., 1999).

Aronson et al., (2006) demonstrated an inverse linear relationship exists between CRP concentrations and measures of pulmonary function in subjects without pulmonary disease and in never-smokers. There was a strong inverse association between CRP levels and quartiles of FEV₁ (Aronson et al., 2006). In our study to the levels of hsCRP was seen to increase with the increasing severity of COPD. Dahl et al., (2007) found that CRP is a strong and independent predictor of future COPD outcomes. Serum CRP was measured at baseline, and COPD admissions and deaths were recorded as outcomes. The number of COPD hospitalizations and COPD death were increased in individuals with baseline CRP > 3 mg/L versus < or = 3 mg/L (Dahl et al., 2007).
Man et al., (2006) concluded CRP measurements provide incremental prognostic information beyond that achieved by traditional markers of prognosis in patients with mild to moderate COPD, and may enable more accurate detection of patients at a high risk of mortality (Man et al., 2006). These findings are in agreement with our results. Hs-CRP was found to be positively correlating with the severity of COPD indicating a more severe disease and intense inflammation in the very severe group.

**Paraoxonase 1 (PON 1) in COPD**

Paraoxonase1 (PON1) is a calcium-dependent esterase closely associated with HDL-containing apoA-I that has been reported to confer antioxidant properties on HDL by decreasing the accumulation of lipid peroxidation products. PON1 activity is under genetic and environmental regulation and appears to vary widely among individuals and populations.
Figure 4: Correlation of hs-CRP with PON 1

Table 1: Demographic Profile of Different Groups

<table>
<thead>
<tr>
<th></th>
<th>Age (yrs)</th>
<th>Ht (cm)</th>
<th>Wt (Kg)</th>
<th>BMI (kg/m²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>24.93 ± 2.79</td>
<td>163.80 ± 7.63</td>
<td>61.80 ±11.05</td>
<td>22.92 ± 3.28</td>
</tr>
<tr>
<td>HS</td>
<td>38.67 ± 9.83</td>
<td>171.47 ± 6.83</td>
<td>68.47 ± 14.08</td>
<td>23.24 ± 4.32</td>
</tr>
<tr>
<td>Mild</td>
<td>52.47 ± 13.35</td>
<td>165.07 ± 6.36</td>
<td>62.47 ± 9.33</td>
<td>23.15 ± 3.20</td>
</tr>
<tr>
<td>Moderate</td>
<td>53.27 ± 18.04</td>
<td>158.73 ± 10.45</td>
<td>58.87 ± 12.13</td>
<td>23.44 ± 3.93</td>
</tr>
<tr>
<td>Severe</td>
<td>58.93 ± 7.38</td>
<td>160.20 ± 7.78</td>
<td>59.40 ± 15.14</td>
<td>22.76 ± 5.06</td>
</tr>
<tr>
<td>V. Severe</td>
<td>55.73 ± 7.83</td>
<td>165.60 ± 6.29</td>
<td>53.27 ± 10.15</td>
<td>19.44 ± 3.71</td>
</tr>
</tbody>
</table>

HS: healthy smokers
V. severe: very severe COPD

Table 2: Levels of systemic inflammatory markers in different stages of COPD

<table>
<thead>
<tr>
<th></th>
<th>hsCRP (mg/L)</th>
<th>PON1 (KU/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0.65 ± 0.43</td>
<td>192.55 ± 54.71</td>
</tr>
<tr>
<td>HS</td>
<td>0.93 ± 0.71</td>
<td>143.26 ± 55.54</td>
</tr>
<tr>
<td>Mild</td>
<td>0.94 ± 0.68</td>
<td>146.18 ± 61.20</td>
</tr>
<tr>
<td>Moderate</td>
<td>2.53 ± 0.61</td>
<td>90.30 ± 29.99</td>
</tr>
<tr>
<td>Severe</td>
<td>4.87 ± 2.22</td>
<td>84.45 ± 34.89</td>
</tr>
<tr>
<td>V. Severe</td>
<td>6.74 ± 5.36</td>
<td>143.19 ± 35.76</td>
</tr>
</tbody>
</table>

Table 3: Mean Values of spirometry parameters in different stages of COPD

<table>
<thead>
<tr>
<th></th>
<th>FEV₁ Pre</th>
<th>FEV₁ post</th>
<th>FVC Pre</th>
<th>FVC Post</th>
<th>FEF₂₅₋₇₅ Pre</th>
<th>FEF₂₅₋₇₅ Post</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>3.30 ± 0.53</td>
<td>3.38 ± 0.51</td>
<td>3.83 ± 0.72</td>
<td>3.88 ± 0.70</td>
<td>4.18 ± 0.89</td>
<td>4.43 ± 0.88</td>
</tr>
<tr>
<td>HS</td>
<td>3.39 ± 0.52</td>
<td>3.46 ± 0.52</td>
<td>4.26 ± 0.47</td>
<td>4.34 ± 0.51</td>
<td>3.44 ± 1.51</td>
<td>3.56 ± 1.69</td>
</tr>
<tr>
<td>Mild</td>
<td>2.49 ± 0.50</td>
<td>2.65 ± 0.58</td>
<td>3.84 ± 0.75</td>
<td>3.89 ± 0.76</td>
<td>1.39 ± 0.52</td>
<td>1.68 ± 0.71</td>
</tr>
<tr>
<td>Moderate</td>
<td>1.57 ± 0.57</td>
<td>1.70 ± 0.62</td>
<td>2.67 ± 0.82</td>
<td>2.80 ± 0.82</td>
<td>0.74 ± 0.40</td>
<td>0.86 ± 0.554</td>
</tr>
<tr>
<td>Severe</td>
<td>0.97 ± 0.25</td>
<td>1.023 ± 0.26</td>
<td>2.17 ± 0.75</td>
<td>2.35 ± 0.80</td>
<td>0.35 ± 0.10</td>
<td>0.36 ± 0.13</td>
</tr>
<tr>
<td>V. Severe</td>
<td>0.67 ± 0.11</td>
<td>0.72 ± 0.12</td>
<td>2.04 ± 0.43</td>
<td>2.18 ± 0.43</td>
<td>0.23 ± 0.06</td>
<td>0.24 ± 0.60</td>
</tr>
</tbody>
</table>
Birgül et al., (2005) concluded paraoxanase activity was significantly lower in COPD patients as compared to control group (Birgül et al., 2005). In our study we also noticed that the level of PON1 decreased with the increasing severity of COPD.

Mackness et al., (1998) showed that higher levels of CRP seem to be generally associated with low levels of PON1 activity, providing a mechanistic link between inflammation and the development of atherosclerosis (Mackness et al., 1998).

In present study PON1 correlated positively with pulmonary function parameters while hsCRP correlated negatively with and pulmonary function parameters.

Conclusion
These results suggest serum PON-1 levels together with estimation of hs CRP may be important in assessing severity in COPD patients. PON 1 and hs-CRP may be explored as markers of COPD deterioration and hospitalizations.

REFERENCES


